Tuesday, July 4, 2017
Results of ASPRE are out.
During last week's Fetal Medicine Foundation (FMF) World Congress in Ljubljana, Slovenia, the results of the 'ASPRE' study were published in The New England Journal of Medicine.
ASPRE was a three-year project funded by the European Union Seventh Framework Program and the Fetal Medicine Foundation. The aim of the study was to investigate if the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia. Preterm preeclampsia is one of the leading causes of maternal and perinatal death and pregnancy complications. The findings of this international multi-center, double-blind, placebo-controlled study showed that treatment with aspirin (150 mg per day) from 11-14 weeks of gestation until 36 weeks of gestation in women at high risk for preterm preeclampsia resulted in a significantly lower incidence of preterm preeclampsia than treatment with placebo.
astraia software gmbh is proud to have participated in this EU-funded project supporting the collection and analysis of this study's data with dedicated study screens and queries. We are happy to see such positive outcome and are looking forward to seeing the results of this study put into practice to improve the health and wellbeing of both mother and child in the future. The published algorithm of this study will be available in astraia soon.
You can download the article from The New England Journal of Medicine.